Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | FBXW7 |
Variant | S396fs |
Impact List | frameshift |
Protein Effect | loss of function - predicted |
Gene Variant Descriptions | FBXW7 S396fs results in a change in the amino acid sequence of the Fbxw7 protein beginning at aa 396 of 707, likely resulting in premature truncation of the functional protein (UniProt.org). S396fs results in increased expression and activity of Myc, Hif1a, and Notch1 compared to wild-type Fbxw7 in cell culture (PMID: 30510140), and therefore, is predicted to lead to a loss of Fbxw7 protein function. |
Associated Drug Resistance | |
Category Variants Paths |
FBXW7 mutant FBXW7 inact mut FBXW7 S396fs |
Transcript | NM_033632.3 |
gDNA | chr4:g.(152329722_152329723) |
cDNA | c.(1186_1185) |
Protein | p.S396fs |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
XM_024454123.2 | chr4:g.(152329722_152329723) | c.(1186_1185) | p.S396fs | RefSeq | GRCh38/hg38 |
XM_024454123.1 | chr4:g.(152329722_152329723) | c.(1186_1185) | p.S396fs | RefSeq | GRCh38/hg38 |
NM_018315.5 | chr4:g.(152326224_152326225) | c.(1186_1185) | p.S396fs | RefSeq | GRCh38/hg38 |
NM_001349798.1 | chr4:g.(152329722_152329723) | c.(1186_1185) | p.S396fs | RefSeq | GRCh38/hg38 |
XM_024454122.1 | chr4:g.(152329722_152329723) | c.(1186_1185) | p.S396fs | RefSeq | GRCh38/hg38 |
XM_047415897.1 | chr4:g.(152329722_152329723) | c.(1186_1185) | p.S396fs | RefSeq | GRCh38/hg38 |
XM_017008362 | chr4:g.(152329722_152329723) | c.(1186_1185) | p.S396fs | RefSeq | GRCh38/hg38 |
XM_024454124.1 | chr4:g.(152329722_152329723) | c.(1186_1185) | p.S396fs | RefSeq | GRCh38/hg38 |
XM_011532084.2 | chr4:g.(152329722_152329723) | c.(1186_1185) | p.S396fs | RefSeq | GRCh38/hg38 |
XM_047415898.1 | chr4:g.(152329722_152329723) | c.(1186_1185) | p.S396fs | RefSeq | GRCh38/hg38 |
XM_011532084 | chr4:g.(152329722_152329723) | c.(1186_1185) | p.S396fs | RefSeq | GRCh38/hg38 |
NM_001349798.2 | chr4:g.(152329722_152329723) | c.(1186_1185) | p.S396fs | RefSeq | GRCh38/hg38 |
XM_011532085.3 | chr4:g.(152329722_152329723) | c.(1186_1185) | p.S396fs | RefSeq | GRCh38/hg38 |
NM_018315 | chr4:g.(152326224_152326225) | c.(1186_1185) | p.S396fs | RefSeq | GRCh38/hg38 |
XM_024454121.1 | chr4:g.(152329722_152329723) | c.(1186_1185) | p.S396fs | RefSeq | GRCh38/hg38 |
XM_047415899.1 | chr4:g.(152329722_152329723) | c.(1186_1185) | p.S396fs | RefSeq | GRCh38/hg38 |
NM_018315.4 | chr4:g.(152326224_152326225) | c.(1186_1185) | p.S396fs | RefSeq | GRCh38/hg38 |
NM_033632.3 | chr4:g.(152329722_152329723) | c.(1186_1185) | p.S396fs | RefSeq | GRCh38/hg38 |
XM_011532083 | chr4:g.(152329722_152329723) | c.(1186_1185) | p.S396fs | RefSeq | GRCh38/hg38 |
XM_011532085 | chr4:g.(152329722_152329723) | c.(1186_1185) | p.S396fs | RefSeq | GRCh38/hg38 |
XM_011532084.3 | chr4:g.(152329722_152329723) | c.(1186_1185) | p.S396fs | RefSeq | GRCh38/hg38 |
XM_047415901.1 | chr4:g.(152329722_152329723) | c.(1186_1185) | p.S396fs | RefSeq | GRCh38/hg38 |
XM_047415900.1 | chr4:g.(152329722_152329723) | c.(1186_1185) | p.S396fs | RefSeq | GRCh38/hg38 |
NM_033632.3 | chr4:g.(152329722_152329723) | c.(1186_1185) | p.S396fs | RefSeq | GRCh38/hg38 |
NM_033632 | chr4:g.(152329722_152329723) | c.(1186_1185) | p.S396fs | RefSeq | GRCh38/hg38 |
XM_011532085.2 | chr4:g.(152329722_152329723) | c.(1186_1185) | p.S396fs | RefSeq | GRCh38/hg38 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|